Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Study of Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors, including Pancreatic Cancer

Summary

The purpose of this trial is to evaluate the safety and efficacy of Tusamitamab ravtansine with and without Gemcitabine in patients with metastatic pancreatic adenocarcinoma.

General Information

NCT#: NCT04659603
Study ID: ACT16432
Trial Phase: Phase II

Trial Sponsor: Sanofi
Therapies Used in This Trial: tusamitamab ravtansine

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search